CD274 and non-small cell lung carcinoma: The recent introduction of immune checkpoint inhibitors (ICIs), namely monoclonal antibodies directed against programmed death receptor 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) monoclonal antibodies, has resulted in an increase in overall survival (OS) rates of patients with advanced NSCLC on the basis of numerous clinical trials [4–10].